2月20日 - ** 远程医疗平台 Mangoceuticals MGRX.O 股价盘前上涨 43% 至 51 美分
** 该公司称，自12月中旬以来，其新的99美元/月注射睾酮治疗计划的销售额比上个月猛增了336%。
** MGRX 称其客户获取成本也降低了一半以上
** Mangoceuticals 预计睾酮疗法将成为其主要增长动力
** 2025 年，MGRX 暴跌 70%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.